Claudia Barate
Milan, 20161, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 66 publications
Zanubrutinib, a New Bullet Against Chronic Lymphocytic Leukemia Even When Localized in Central Nervous System.
Journal: Case reports in hematology
Published: August 06, 2025
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice.
Journal: Haematologica
Published: March 20, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.
Journal: Hematological oncology
Published: February 14, 2025
Management of infections for patient treated with ibrutinib in clinical practice.
Journal: Frontiers in oncology
Published: May 06, 2024
A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.
Journal: Pharmaceutics
Published: January 07, 2024
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.
Journal: Annals of hematology
Published: August 25, 2023
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Journal: Hematological oncology
Published: April 07, 2023
Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.
Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.
Journal: Clinical and experimental medicine
Published: February 24, 2023
Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: January 17, 2023
Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease.
Journal: Journal of clinical medicine
Published: December 12, 2022
Last Updated: 09/26/2026